ResMed Inc (RMD)

Currency in USD
211.94
-11.30(-5.06%)
Closed·
211.940.00(0.00%)
·
Unusual trading volume
RMD is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
202.00215.50
52 wk Range
180.26293.81
Key Statistics
Prev. Close
223.24
Open
207.18
Day's Range
202-215.5
52 wk Range
180.26-293.81
Volume
3.81M
Average Volume (3m)
1.53M
1-Year Change
-25.347%
Book Value / Share
45.6
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
RMD Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
247.20
Upside
+16.64%
Members' Sentiments
Bearish
Bullish
ProTips
Has raised its dividend for 14 consecutive years

ResMed Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Strong Sell
Moving Averages
Neutral

Analyst Ratings

7 Buy
10 Hold
1 Sell
Ratings:
18 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 247.20
(+16.64% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Wells Fargo
Hold215.00+1.44%225.00Maintain07-08-2026
Piper Sandler
Hold225.00+6.16%233.00Maintain07-08-2026
RBC Capital
Hold244.00+15.13%234.00Maintain07-08-2026
KeyBanc
Buy255.00+20.32%260.00Maintain07-08-2026
UBS
Buy300.00+41.55%312.00Maintain21-07-2026

ResMed Inc SWOT Analysis


Sleep Tech Dominance
ResMed's strong market position in sleep and respiratory care, driven by innovative products like AirSense 11, faces potential disruption from emerging GLP-1 drugs
Financial Resilience
Explore ResMed's impressive financial performance, with double-digit revenue growth and improved operating margins, despite challenges in gross margins
Market Expansion
Delve into ResMed's strategic moves beyond sleep apnea, targeting insomnia and COPD markets to diversify revenue streams and offset potential market share losses
Analyst Perspectives
Price targets range from $180 to $280, reflecting varied views on ResMed's ability to navigate challenges from GLP-1 drugs and increased competition
Read full SWOT analysis

ResMed Inc Earnings Call Summary for Q4/2026

  • ResMed Q4 non-GAAP EPS rose 16% YoY to $2.95, beating estimates by $0.06; revenue up 9% to $1.46B but missed by $10M, triggering 5.93% after-hours drop.
  • Gross margin improved 90bps to 62.3% on supply-chain gains; FY2026 full-year revenue grew 10% with non-GAAP EPS up 17%, ROE at 25%.
  • Company issued first-ever guidance: FY2027 revenue $5.75B-$5.85B, non-GAAP EPS $12.00-$12.25; core growth 5%-7% excluding portfolio changes.
  • Astral field safety action creates $75M FY2027 revenue headwind; $42M provision taken in Q4, with no new Astral sales planned for fiscal year.
  • ResMed raised dividend 10% to $0.66/share, plans $1.5B stock buyback in FY2027 including $450M accelerated repurchase tied to MatrixCare divestiture.
Last Updated: 07-08-2026, 03:32 am
Read Full Transcript

Earnings

Latest Release
06-08-2026
EPS / Forecast
2.95 / 2.89
Revenue / Forecast
1.46B / 1.47B
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 10.43%
Dividend Yield
1.08%
Industry Median 1.47%
Annualised payout
2.40
Paid quarterly
5-Years Growth
+8.35%
Growth Streak

RMD Income Statement

Compare RMD to Peers and Sector

Metrics to compare
RMD
Peers
Sector
Relationship
P/E Ratio
20.1x21.3x−0.4x
PEG Ratio
2.070.300.00
Price/Book
4.6x2.1x2.6x
Price / LTM Sales
5.4x1.9x3.1x
Upside (Analyst Target)
10.9%0.0%48.8%
Fair Value Upside
Unlock23.2%5.7%Unlock

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software. It offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients’ device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
65.33M45.29%13.85B
Other Institutional Investors
47.17M32.70%10.00B
Public Companies & Retail Investors
31.74M22.01%6.73B
Total
144.25M100.00%30.57B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
BlackRock, Inc.8.52%1,22,86,35726,03,971
Vanguard Capital Management, LLC7.13%1,02,91,49221,81,179

FAQ

What Is the ResMed (RMD) Share Price Today?

The ResMed share price today is 211.94.

What is the current ResMed (RMD) share price and day range?

As of 09-08-2026, the ResMed share price is 211.94, with a previous close of 223.24. The share price has ranged from 202.00 to 215.50 today, while the 52-week range spans from 180.26 to 293.81.

What Is the ResMed Market Cap?

As of today, ResMed market cap is 30.57B.

Does ResMed Pay Dividends? What's The Current Dividend Yield?

The ResMed dividend yield is 1.25%.

What Is the ResMed (RMD) Share Price Target?

The average 12-month share price target for ResMed is 247.20, with a high estimate of 325 and a low estimate of 175. 7 analysts recommend buying, while 1 suggest selling, with an overall rating of Buy and +16.64% Upside potential.

What Is ResMed's Earnings Per Share (TTM)?

The ResMed EPS (TTM) is 10.43.

When Is the Next ResMed Earnings Date?

ResMed will release its next earnings report on 22-10-2026.

From a Technical Analysis Perspective, Is RMD a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

What Stock Exchange Does ResMed Trade On?

ResMed is listed and trades on the New York Stock Exchange.

What Is the Stock Symbol for ResMed?

The stock symbol for ResMed is "RMD."

How Many Times Has ResMed Stock Split?

ResMed has split 4 times.

How Many Employees Does ResMed Have?

ResMed has 10600 employees.

What Is the RMD Premarket Price?

RMD's last pre-market stock price is 205.64. The pre-market share volume is 39,690.00, and the stock has changed by -17.60, or -7.88%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.